Overview

Isolated Liver Perfusion With Oxaliplatin

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The primary goal of this research study is to determine a safe dose for the drug oxaliplatin when delivered by isolated hepatic perfusion. The second goal of this research study is to determine if isolated hepatic perfusion with oxaliplatin can improve the efficacy of standard hepatic arterial infusional (HAI) therapy with floxuridine (FUDR)/leucovorin.
Phase:
Phase 1
Details
Lead Sponsor:
David Bartlett
Collaborators:
Sanofi
The Pittsburgh Foundation
Treatments:
Oxaliplatin